NASDAQ:RNA Avidity Biosciences Q2 2026 Earnings Results & Report $8.40 +0.14 (+1.69%) As of 10/9/2026 04:00 PM Eastern Avidity Biosciences beat analyst expectations on both earnings and revenue in its Q2 2026 results, released August 13, 2026. The company reported EPS of -$1.18 versus the -$1.42 consensus estimate, while revenue of $3.00 million topped the $0.67 million estimate by $2.34 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 13, 2026TimeAfter Market ClosesConference Call4:00 PM ET Avidity Biosciences EPS ResultsActual EPS-$1.18Consensus EPS -$1.42Beat/MissBeat by +$0.24One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersAvidity Biosciences Revenue ResultsActual Revenue$3.00 millionExpected Revenue$0.67 millionBeat/MissBeat by +$2.34 millionYoY Revenue GrowthN/AUpcoming EarningsAvidity Biosciences' Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Avidity Biosciences Q2 2026 Earnings FAQ Did Avidity Biosciences beat earnings estimates for Q2 2026? Avidity Biosciences (NASDAQ:RNA) reported earnings of -$1.18 per share for Q2 2026, beating the consensus estimate of -$1.42. The report was announced on Thursday, August 13, 2026. What was Avidity Biosciences' revenue for Q2 2026? Avidity Biosciences reported revenue of $3.00 million for Q2 2026, against a consensus estimate of $0.67 million. When is Avidity Biosciences' next earnings date? Avidity Biosciences' next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for Avidity Biosciences on the company's earnings history page. Avidity Biosciences Earnings HeadlinesAtrium Therapeutics Announces $50 Million Private PlacementOctober 8 at 6:30 AM | prnewswire.comAvidity Biosciences (NASDAQ:RNA) Stock Price Crosses Below 200-Day Moving Average - Here's What HappenedOctober 7, 2026 | americanbankingnews.comDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.October 11 at 1:00 AM | Stansberry Research (Ad)Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)September 21, 2026 | prnewswire.comNovartis RNA drug falls short in rare muscle disease studySeptember 9, 2026 | finance.yahoo.comAtrium Therapeutics to Participate in Upcoming Investor ConferencesSeptember 2, 2026 | prnewswire.comSee More Avidity Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Avidity Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Avidity Biosciences and other key companies, straight to your email. Email Address About Avidity BiosciencesAvidity Biosciences (NASDAQ:RNA) is a clinical-stage biopharmaceutical company focused on developing genetic medicines for diseases that have historically been difficult to treat with conventional approaches. The company’s technology platform, known as Antibody Oligonucleotide Conjugates (AOCs), combines the targeting capabilities of antibodies with oligonucleotide-based medicines designed to act on RNA inside specific cells. Avidity’s research programs are primarily directed at serious muscle diseases, including myotonic dystrophy type 1, facioscapulohumeral muscular dystrophy and Duchenne muscular dystrophy. Its pipeline has included delpacibart etedesiran, also known as AOC 1001, an investigational therapy designed to deliver an oligonucleotide to skeletal and cardiac muscle for the treatment of myotonic dystrophy type 1. The company is also advancing additional AOC-based candidates intended to address genetic disorders affecting muscle tissue. Founded in 2012 and headquartered in San Diego, California, Avidity conducts discovery, development and clinical-stage activities primarily in the United States. The company’s programs remain investigational, and its AOC platform is intended to expand the range of tissues that can be reached by RNA-targeting medicines. Sarah Boyce serves as Avidity Biosciences’ president and chief executive officer.View Avidity Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Q3 Earnings Could Blow Past Consensus—Be Ready for What Comes NextDelta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis Reform Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
